Europe’s divisional patent strategy is quietly reshaping the generics market—and Big Pharma is using it to delay the moment that matters most: the final decision.
Here’s the agitation: when patients, payers, and policymakers talk about “patent cliffs,”…

Pharma patent litigation used to be a “necessary evil.” Now it’s becoming a board-level line item that can’t be ignored.
DrugPatentWatch’s latest piece makes a blunt point: cutting pharma patent litigation costs from $50M to $5M isn’t a theoretical exe…

PBMs and rebates aren’t “background noise” anymore—they’re the operating system of modern pharma economics.
Here’s the agitation: if you’re a pharma executive still thinking about formularies as a marketing checkbox—something you “manage” after the fac…

Mark Cuban’s “cost-plus” pricing isn’t just a new way to buy drugs—it’s a direct challenge to the patent playbook that has quietly governed U.S. healthcare for decades.
For years, the industry’s economics have been built on a familiar sequence: patent …

Should you file a provisional patent for your drug invention? The honest answer.
Most founders in biotech don’t lose sleep over the science—they lose sleep over the paperwork. The question that keeps coming up in founder circles, investor calls, and co…

Don’t Wait for the Patent Cliff. Build Supply-Chain Resilience Years Before Drug Patent Expiration.
The patent cliff isn’t coming—it’s already in motion.
For pharma leaders, the moment a blockbuster’s exclusivity window starts to narrow, the industry’s…

The 180-Day FDA Exclusivity Race Isn’t a Sprint—It’s a Legal-Commercial War Game
In generic and biosimilar development, everyone talks about the science. But the real determinant of who wins the 180-day FDA exclusivity “race” is usually something less …

Pharma is still missing the point of the PBM endgame.
Mark Cuban didn’t just “get lucky” with his critique of pharmacy benefit managers—he identified a structural truth: the PBM model is optimized for margin extraction, not patient outcomes. And while …

What long-term joint problems have been reported with Lipitor (atorvastatin)? Long-term joint side effects from Lipitor… https://www.Drugchatter.com/chat/47878/what-are-lipitor’s-long-term-joint-effects/

What long-term joint problems have been reported with Lipitor (atorvastatin)? Long-term joint side effects from Lipitor… https://www.Drugchatter.com/chat/47878/what-are-lipitor’s-long-term-joint-effects/